http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#Head
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#assertion
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#provenance
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#pubinfo
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#assertion
http://purl.obolibrary.org/obo/DOID_0060224
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_0060224
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00489
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association
http://www.w3.org/2000/01/rdf-schema#label
sotalol hydrochloride tablets usp are indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia that in the judgment of the physician are life threatening because of the proarrhythmic effects of sotalol hydrochloride tablets see warnings initiation of sotalol hydrochloride tablet usp treatment or increasing doses as with other antiarrhythmic agents used to treat life threatening arrhythmias should be carried out in the hospital the response to treatment should then be evaluated by a suitable method e g pes or holter monitoring prior to continuing the patient on chronic therapy various approaches have been used to determine the response to antiarrhythmic therapy including sotalol hydrochloride tablets usp in the esvem trial response by holter monitoring was tentatively defined as 1 suppression of ventricular tachycardia 9 suppression of non sustained vt 8 suppression of paired vpcs and 75 suppression of total vpcs in patients who had at least 1 vpcs hour at baseline this tentative response was confirmed if vt lasting 5 or more beats was not observed during treadmill exercise testing using a standard bruce protocol the pes protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites response by pes was defined as prevention of induction of the following 1 monomorphic vt lasting over 15 seconds 2 non sustained polymorphic vt containing more than 15 beats of monomorphic vt in patients with a history of monomorphic vt 3 polymorphic vt or vf greater than 15 beats in patients with vf or a history of aborted sudden death without monomorphic vt and 4 two episodes of polymorphic vt or vf of greater than 15 beats in a patient presenting with monomorphic vt sustained vt or nsvt producing hypotension during the final treadmill test was considered a drug failure in a multicenter open label long term study of sotalol hydrochloride tablets usp in patients with life threatening ventricular arrhythmias which had proven refractory to other antiarrhythmic medications response by holter monitoring was defined as in esvem response by pes was defined as non inducibility of sustained vt by at least double extrastimuli delivered at a pacing cycle length of 4 msec overall survival and arrhythmia recurrence rates in this study were similar to those seen in esvem although there was no comparative group to allow a definitive assessment of outcome antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias sotalol is also indicated for the maintenance of normal sinus rhythm delay in time to recurrence of atrial fibrillation atrial flutter afib afl in patients with symptomatic afib afl who are currently in sinus rhythm and is marketed under the brand name betapace af sotalol hydrochloride tablets usp are not approved for the afib afl indication and should not be substituted for betapace af because only betapace af is distributed with a patient package insert that is appropriate for patients with afib afl
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00489
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#provenance
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#pubinfo
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#sig
http://purl.org/nanopub/x/hasSignature
I/n/RqGCpDq+orpUprVePQDe8SPvxwurPNlTMIKCFoL+1WNYdHO5QDpsxY41gZgWM4u6C1f1V3mJZnG8iiyoL+KxsraqOsqNB9cYWAlni/HJLoNivDOoKSM127Uyo0bSfO0VYdvGBWkc6T/QMfwFYV6bdQvIYVltQqOqexTvFuQ=
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg
http://purl.org/dc/terms/created
2021-07-03T11:35:14.650+02:00
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RAXELo0q6b-LaEm0dW-pby4P2nn4dLW3Aa_ImvOgR6GYg
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs